Lupus & antiphospholipid syndrome
A 12-month follow-up study of patients with systemic lupus erythematosus after immunization against SARS-CoV-2
Authors' conclusion
33 of 100 SLE patients immunized with BNT162b2 vaccine against SARS-CoV-2, presented SLE flares (47 episodes in total); 5 of these patients required in-hospital management and all fully recovered; 26 patients had SARS-CoV-2 infection; three required hospitalization, one died.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) from the Immuno-Rheumatology Department cohort, Cayetano Heredia Hospital, Lima, Perú, vaccinated with BNT162b2 (May–June 2021)
- Participants
- 100 patients
- Outcome
- All post-BNT162b2 vaccination events
- Follow-up
- 12 months
Methodological details12-month follow-up, single-centre, 100 received 1st dose, 90 2nd dose, 85 3rd dose
- 12-month follow-up
- Single-centre
- 100 received 1st dose, 90 2nd dose, 85 3rd dose
Main finding
As reported in the abstract
SLE flare after BNT162b2 vaccination
- Patients with SLE flare
- 33
- Flare post 1st dose (9/100)
- 9%
- Flare post 2nd dose (24/90)
- 26.6%
- Flare post 3rd dose (14/85)
- 16.4%
- Articular flares
- 26
- Renal flares
- 14
- Flare episodes in total
- 47
Observational data: associations, not effects.
Further findings
Association of drug use with flare occurrence
| RR (CI) | ||
|---|---|---|
| HCQ useNegative association | 0.43 (0.21–0.85) | |
| AZA use | 2.70 (1.39–5.25) | |
| 0.20.5125Relative risk (log scale) |
Safety
Hospitalisation for flare management
- Patients requiring hospitalisation for flare (5/33)
- 15.1%
- All fully recovered
SARS-CoV-2 infection during follow-up
- Patients with SARS-CoV-2 infection
- 26
- Required hospitalisation
- 3
- Died
- 1
Original publication
A 12-month follow-up study of patients with systemic lupus erythematosus after immunization against SARS-CoV-2. Lupus. Published 18 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →